[go: up one dir, main page]

HK1206351A1 - Cycloalkyl ether compounds and their use as bace inhibitors - Google Patents

Cycloalkyl ether compounds and their use as bace inhibitors Download PDF

Info

Publication number
HK1206351A1
HK1206351A1 HK15106987.5A HK15106987A HK1206351A1 HK 1206351 A1 HK1206351 A1 HK 1206351A1 HK 15106987 A HK15106987 A HK 15106987A HK 1206351 A1 HK1206351 A1 HK 1206351A1
Authority
HK
Hong Kong
Prior art keywords
disease
dementia
alzheimer
compounds
ether compounds
Prior art date
Application number
HK15106987.5A
Other languages
English (en)
Chinese (zh)
Inventor
Sofia KARLSTRÖM
Peter SÖDERMAN
Britt-Marie Swahn
Laszlo Rakos
Liselotte ÖHBERG
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1206351A1 publication Critical patent/HK1206351A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15106987.5A 2012-06-20 2013-06-20 Cycloalkyl ether compounds and their use as bace inhibitors HK1206351A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661923P 2012-06-20 2012-06-20
US61/661,923 2012-06-20
PCT/GB2013/051605 WO2013190301A1 (fr) 2012-06-20 2013-06-20 Composés cycloalkyle-éther et leur utilisation en tant qu'inhibiteurs de bace

Publications (1)

Publication Number Publication Date
HK1206351A1 true HK1206351A1 (en) 2016-01-08

Family

ID=48699191

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106987.5A HK1206351A1 (en) 2012-06-20 2013-06-20 Cycloalkyl ether compounds and their use as bace inhibitors

Country Status (7)

Country Link
US (1) US9000185B2 (fr)
EP (1) EP2864298A1 (fr)
JP (1) JP2015520220A (fr)
CN (1) CN104507915A (fr)
CA (1) CA2874950A1 (fr)
HK (1) HK1206351A1 (fr)
WO (1) WO2013190301A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2013054108A1 (fr) 2011-10-10 2013-04-18 Astrazeneca Ab Inhibiteurs de mono fluoro-bêta-secretase
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2019129755A1 (fr) * 2017-12-29 2019-07-04 Astrazeneca Ab Hydrogénation de cétal

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332184T3 (es) 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
PE20070135A1 (es) 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
JP2009521488A (ja) 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
WO2007100536A1 (fr) 2006-02-24 2007-09-07 Wyeth COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE
WO2008076044A1 (fr) 2006-12-20 2008-06-26 Astrazeneca Ab Nouveaux 2-amino-5, 5-diaryl-imidazol-4-ones
WO2009100169A1 (fr) 2008-02-06 2009-08-13 Glaxo Group Limited Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010021680A2 (fr) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibiteurs de la bêta-sécrétase
CN102209721A (zh) 2008-09-11 2011-10-05 安姆根有限公司 作为β-分泌酶调节剂的螺四环化合物及其使用方法
MX2011009571A (es) 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
TW201105650A (en) 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
UY32750A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
WO2011106414A1 (fr) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibiteurs de la bêta-secrétase
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
WO2011130741A1 (fr) 2010-04-16 2011-10-20 Array Biopharma Inc. Composés pour le traitement de maladies neurodégénératives
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
WO2012040641A2 (fr) 2010-09-24 2012-03-29 Array Biopharma Inc. Composés de traitement de maladies neurodégénératives
WO2012071458A1 (fr) 2010-11-22 2012-05-31 Array Biopharma Inc. Inhibiteurs hétérocycliques de la bêta-secrétase pour le traitement de maladies neurodégénératives
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt

Also Published As

Publication number Publication date
US9000185B2 (en) 2015-04-07
WO2013190301A1 (fr) 2013-12-27
CN104507915A (zh) 2015-04-08
JP2015520220A (ja) 2015-07-16
US20130345272A1 (en) 2013-12-26
CA2874950A1 (fr) 2013-12-27
EP2864298A1 (fr) 2015-04-29

Similar Documents

Publication Publication Date Title
SA114360153B1 (ar) مركبات واستخدامها كمثبطات bace
HK1206351A1 (en) Cycloalkyl ether compounds and their use as bace inhibitors
HK1206350A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
HK1206347A1 (en) Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors
WO2012080727A3 (fr) Inhibiteurs de caséine kinase 1 delta (ck1delta)
WO2012075492A3 (fr) Purine substituée par un carbocycle et composés de 7-déazapurine
WO2013064900A8 (fr) Compositions pharmaceutiques pour des quinazolinones substituées
WO2016172134A3 (fr) Nouveaux composés
IN2014DN03206A (fr)
HK1206348A1 (en) Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
HK1212348A1 (en) Autotaxin inhibitors
HK1206597A1 (en) Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
MX2015004947A (es) Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
NZ702742A (en) Camsylate salt of (1r,1’r,4r)- 4-methoxy-5’’-methyl-6’-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3’h-dispiro[cyclohexane-1,2’-indene-1’,2’’-imidazol]-4’’-amine
WO2013188268A8 (fr) Composition pharmaceutique ophtalmique topique contenant du pazopanib
WO2011023367A3 (fr) Promédicaments bisphosphonates
MX2013011421A (es) Derivados de pirazolo-pirimidina.
WO2014035846A3 (fr) Composés azaindole substitué, leurs sels, leurs compositions pharmaceutiques et leurs procédés d'utilisation
WO2011112535A3 (fr) Acides propioniques, esters d'acides propioniques et composés apparentés
WO2013188279A8 (fr) Composition pharmaceutique ophtalmique topique contenant du cediranib
HK1200456A1 (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands
WO2012122451A3 (fr) Polymorphes de maxacalcitol et procédé de préparation de maxacalcitol
NZ728660A (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
HK1210173A1 (en) Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
WO2014082738A8 (fr) Hétéroquinoline-3-carboxamides utilisés en tant que modulateurs kcnq2/3